PepGen Inc. (PEPG)
2.47
+0.15
(+6.47%)
USD |
NASDAQ |
Nov 06, 16:00
2.51
+0.04
(+1.62%)
After-Hours: 20:00
PepGen Research and Development Expense (Annual) : 69.65M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 69.65M |
| December 31, 2024 | 74.97M |
| December 31, 2023 | 66.94M |
| December 31, 2022 | 53.58M |
| Date | Value |
|---|---|
| December 31, 2021 | 18.82M |
| December 31, 2020 | 0.914M |
| December 31, 2019 | 0.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Korsana Biosciences, Inc. | 0.959M |
| IRulya Therapeutics, Inc. | 35.38M |
| Q32 Bio, Inc. | 19.16M |
| Bridgebio Oncology Therapeutics, Inc. | 121.20M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |